Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

Rhea-AI Summary

Nuvation Bio (NYSE: NUVB) will report first quarter 2026 financial results and provide a business update on May 4, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET for investors and the public.

Participants can register via the company Investor Relations website, join the call +1 833-461-5787 (U.S. toll-free) with access code 266802059, and review an archived recording for 90 days.

News Market Reaction – NUVB

-0.20%

-0.20% Session close to close

In the Apr 21 session, NUVB declined 0.20%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the schedule for Nuvation Bio’s Q1 2026 results and business update on May 4,...

Analysis

This announcement sets the schedule for Nuvation Bio’s Q1 2026 results and business update on May 4, 2026 at 4:30 p.m. ET, with access via webcast and a 90-day replay. Historically, similar earnings date notices produced modest stock moves, while the subsequent earnings release on March 2, 2026 saw a larger reaction. Investors may focus on the forthcoming Q1 details rather than the timing, watching for updates on clinical programs and financial runway.

Key Figures

Earnings call date: May 4, 2026 Earnings call time: 4:30 p.m. ET Webcast archive length: 90 days +2 more

5 metrics

Earnings call date May 4, 2026 Scheduled Q1 2026 results and business update

Earnings call time 4:30 p.m. ET Start time for Q1 2026 conference call

Webcast archive length 90 days Replay availability on company website

Conference call number +1 833-461-5787 U.S. toll-free dial-in for Q1 2026 call

Access code 266802059 Access code for live conference call

Previous Earnings date Reports

1 past event · Latest: Feb 17 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 17	Earnings date notice	Neutral	-1.9%	Scheduled Q4 and full-year 2025 results call on March 2, 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings date scheduling news saw a modest negative reaction, suggesting timing announcements alone have not consistently driven upside.

Recent Company History

Recent news for Nuvation Bio shows active corporate and clinical progress. An earlier earnings date notice on Feb 17, 2026 preceded Q4/FY 2025 results that eventually saw a -25.34% move after the Mar 2 earnings release. Since then, the company announced investor conference participation, pivotal IBTROZI® data at AACR, an EMA MAA validation for taletrectinib, and acquisition of Japan rights to safusidenib. Today’s Q1 2026 earnings date notice fits into this steady cadence of updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the first quarter of 2026.

Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (U.S. toll-free) and enter access code 266802059. An archived recording will be available on Nuvation Bio's website for 90 days following the event.

About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI^®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. 

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc). 

Media and Investor Contacts

Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com

Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-4-2026-302747586.html

SOURCE Nuvation Bio Inc.

FAQ

When will Nuvation Bio (NUVB) release Q1 2026 results and host the webcast?

The company will report Q1 2026 results and host a webcast on May 4, 2026 at 4:30 p.m. ET. According to Nuvation Bio, the event will cover first quarter financial results and a business update for investors and the public.

How can investors access the NUVB May 4, 2026 conference call and webcast?

Investors may join the live webcast via the company's Investor Relations site or dial +1 833-461-5787 with access code 266802059. According to Nuvation Bio, registration is available on its Investor Relations webpage before the event.

Will Nuvation Bio (NUVB) provide a recording of the May 4, 2026 webcast?

Yes, an archived recording will be available on the company website for 90 days after the event. According to Nuvation Bio, the recording will be posted to the Investor Relations section following the live webcast.

What topics will Nuvation Bio (NUVB) cover during the May 4, 2026 presentation?

The presentation will discuss Q1 2026 financial results and a company business update. According to Nuvation Bio, management will review performance and recent corporate developments relevant to investors.

Is the Nuvation Bio (NUVB) May 4, 2026 call open to the general public?

Yes, the live webcast and conference call are open to investors and the general public. According to Nuvation Bio, anyone may listen by registering on the Investor Relations website or dialing the provided U.S. toll-free number.